All Stories

Boston biotech Bambusa banks $90M for next-gen bispecifics

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions.

Feb 14, 2025 - 17:21
 0
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions.
Read More

Tags:

Previous Article

Moderna shoulders $238M contract manufacturing cancellation charge in Q4

Next Article

CDC to lose one-tenth of workforce under Trump administration probationary job cuts

Related Posts

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

Biogen axes asset from $7.3B buyout, along with Alzheim...

Feb 12, 2025  0

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in ...

Feb 12, 2025  0

Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials

Polish biotech Ryvu waves goodbye to 30% of staff in fo...

Feb 25, 2025  0